americanpharmaceuticalreviewOctober 10, 2020
Tag: Moleculin , HIV , WP1096 , WP1097 , SARS-CoV-2
Moleculin Biotech announced preliminary new findings from its research collaboration with the Rega Institute in Leuven, Belgium, that demonstrate its drug candidates, WP1096 and WP1097, are showing in vitro activity in a range of infectious diseases. In addition to activity against SARS-CoV-2, antiviral activity has now been documented for HIV, Zika and Dengue Fever.
WP1096 and its close analog, WP1097, are structurally slightly different agents within the Company's WP1122 portfolio. While the Company is continuing its preclinical development work on WP1122, including in vivo testing for SARS-CoV-2, it has now expanded its infectious disease program to include these two molecules. In addition, the Company continues to drive the clinical development of Annamycin, which is currently being studied for the treatment of relapsed or refractory acute myeloid leukemia, and WP1066, which targets brain tumors, pancreatic cancer and hematologic malignancies.
"We recently announced the discovery that these new molecules have significant in vitro activity in SARS-CoV-2 that may be due to mechanistic differences from other molecules in the WP1122 portfolio. Now, we are looking at the possibility that our portfolio of antimetabolites can address a wide range of infectious diseases beyond COVID-19," Walter Klemp, Chairman and CEO of Moleculin, said. "In the case of Zika and Dengue Fever, there are no viable therapies, so we think this study garners the potential to involve possible governmental entities to assist in the development of and provide funding for the first ever treatments for these important diseases."
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: